[Chinese expert consensus on the clinical application of next-generation sequencing technology in myelodysplastic neoplasms (2026)].

Myelodysplastic neoplasms (MDS) are a group of highly heterogeneous myeloid malignancies characterized by cytopenia, dysplasia, and a high risk of leukemic transformation. Next-generation sequencing (NGS) technology enables efficient detection of gene mutations and has been incorporated into the diagnostic classification, prognostic assessment, and treatment decision-making systems for MDS. To further standardize the clinical application of NGS technology in MDS, Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association have developed this expert consensus by integrating the latest advances in MDS diagnosis and treatment, relevant domestic and international guidelines/consensus recommendations, and expert opinions from China. The aim is to promote the rational use of NGS in the diagnosis and treatment of MDS in China.